DS-103

DS-103 is an inhibitor for HDAC that inhibits HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8 with IC50s of 0.029, 0.123, 0.022, 0.367 and 9.26 μM, respectively. DS-103 inhibits Plasmodium falciparum 3D7 with IC50 of 5.08 μM. DS-103 exhibits cytotoxicity in cells A2780 and Cal27 with IC50 of 1.48 μM and 1.47 μM, reverses Cisplatin resistance in A2780 and Cal27 with IC50 of 4.62 μM and 2.23 μM. DS-103 exhibits synergistic effect with Cisplatin (HY-17394), enhances Cisplatin-induced apoptosis[1].

Product Specifications

UNSPSC

12352005

Target

HDAC; Parasite

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Epigenetics

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection

Smiles

O=C(N(CC1=CC=C(C=C1)C(NNCC)=O)CC(NCC2=CC=CC=C2)=O)C3=CC=C(C=C3)N(C)C

Molecular Formula

C28H33N5O3

Molecular Weight

487.59

References & Citations

[1]Stopper D, et al., Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers DS-103 as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties. J Med Chem. 2025 Feb 27;68 (4) :4426-4452.